



RETURN BIDS TO:

RETOURNER LES SOUMISSIONS À:

Bid Receiving - PWGSC / Réception des soumissions -
TPSGC

11 Laurier St. / 11, rue Laurier

Place du Portage, Phase III

Core 0B2 / Noyau 0B2

Gatineau, Québec K1A 0S5

Bid Fax: (819) 997-9776

SOLICITATION AMENDMENT MODIFICATION DE L'INVITATION

The referenced document is hereby revised; unless otherwise
indicated, all other terms and conditions of the Solicitation
remain the same.

Ce document est par la présente révisé; sauf indication contraire,
les modalités de l'invitation demeurent les mêmes.

Comments - Commentaires

Vendor/Firm Name and Address

Raison sociale et adresse du
fournisseur/de l'entrepreneur

Issuing Office - Bureau de distribution

Drugs, Vaccines and Biologics Division/Div.des
produits pharmaceutiques,biologiques et de vaccins
Terrasses de la Chaudière 5th Floo
10 Wellington Street
Gatineau
Quebec
K1A 0S5

| | |
|---|---|
| Title - Sujet Annual Influenza Vaccine Vaccins annuels antigrippal | |
| Solicitation No. - N° de l'invitation E60PH-22GFLU/A | Amendment No. - N° modif. 003 |
| Client Reference No. - N° de référence du client E60PH-22GFLU | Date 2022-01-17 |
| GETS Reference No. - N° de référence de SEAG PW-\$\$\$PH-896-80749 | |
| File No. - N° de dossier ph896.E60PH-22GFLU | CCC No./N° CCC - FMS No./N° VME |
| Solicitation Closes - L'invitation prend fin at - à 02:00 PM Eastern Standard Time EST on - le 2022-01-26 Heure Normale du l'Est HNE | |
| F.O.B. - F.A.B. Plant-Usine: <input type="checkbox"/> Destination: <input checked="" type="checkbox"/> Other-Autre: <input type="checkbox"/> | |
| Address Enquiries to: - Adresser toutes questions à: Baird, Christa | Buyer Id - Id de l'acheteur ph896 |
| Telephone No. - N° de téléphone (343) 551-3348 () | FAX No. - N° de FAX () - |
| Destination - of Goods, Services, and Construction: Destination - des biens, services et construction: SEE HEREIN | |

Instructions: See Herein

Instructions: Voir aux présentes

| | |
|--|--|
| Delivery Required - Livraison exigée | Delivery Offered - Livraison proposée |
| Vendor/Firm Name and Address Raison sociale et adresse du fournisseur/de l'entrepreneur | |
| Telephone No. - N° de téléphone Facsimile No. - N° de télécopieur | |
| Name and title of person authorized to sign on behalf of Vendor/Firm (type or print) Nom et titre de la personne autorisée à signer au nom du fournisseur/ de l'entrepreneur (taper ou écrire en caractères d'imprimerie) | |
| Signature | Date |

Solicitation amendment #003 is raised to; re-post Q3 and A3 as part of the question was missing, revise the estimated quantities due to a decrease in total demand and extend the closing date.

Q3: Under section 1.11(g): it is stated that "To ensure security of supply, Canada, at its sole discretion, reserves the right to limit a Bidder's aggregate AIV contract quantities, including those awarded under this solicitation to 60% of Canada's estimated public market AIV demand.

Does this include flu vaccines procured through other AIV contracts (including specialized influenza vaccines) as part of the calculation of the 60% doses?

A3: Canada's estimated public market AIV demand is defined under 1.11 Basis of Selection, sub-section (g), paragraph 2. The 60% limitation does not include specialized influenza vaccines such as live attenuated, cell derived and those specifically targeted for persons aged 65 years and older.

REPLACE Part 1 – Information and Instructions, 1.1 Summary with the following:

1.1 Summary

This bid solicitation is for an estimated requirement of:

- (a) **6,125,000** doses of Quadrivalent Influenza Vaccine (QIV) with an age indication of 6 months of age and older (PFS Item 1a and MDV Item 1b)
- (b) **1,340,000** doses of Quadrivalent Influenza Vaccine (QIV) with an age indication of 5 years of age and older (PFS Item 2a and MDV Item 2b)

Up to a maximum of two (2) contracts will be awarded for each items 1a, 1b and 2b. One contract will be awarded for item 2a. Resulting contracts will be from date of award to March 31, 2023 plus two additional one-year option periods.

The quantities provided below are only an approximation of requirements given in good faith and are subject to change prior to Contract award. Each Identified User reserves the right to alter quantities or to withdraw from participation up until Contract award. A significant change in the Requirement for an item may result in a decision to re-tender that item.

| Item | Format | Contract Term (Year 1) 2022-2023 | Option Year 1 (Year 2) 2023-2024 | Option Year 2 (Year 3) 2024-2025 |
|-----------------|--------|--|--|--|
| 1a - QIV (6mo+) | PFS | 1,725,000 | 1,725,000 | 1,750,000 |
| 1b - QIV (6mo+) | MDV | 4,400,000 | 4,400,000 | 4,400,000 |
| 2a - QIV (5yr+) | PFS | 340,000 | 340,000 | 340,000 |
| 2b - QIV (5yr+) | MDV | 1,000,000 | 1,000,000 | 1,000,000 |

REPLACE Part 1 – Information and Instructions, 1.11 Basis of Selection, sub-paragraph (g) with the following:

- (g) To ensure security of supply, Canada, at its sole discretion, reserves the right to limit a Bidder's aggregate AIV contract quantities, including those awarded under this solicitation to 60% of Canada's estimated public market AIV demand.

Canada's estimated public market AIV demand is the total of publicly funded provincial, territorial and federal AIV demand (excluding specialized influenza vaccines such as live attenuated, cell derived and those specifically targeted for persons aged 65 years and older), which is estimated at 11,465,000 doses.

REPLACE Attachment 1 to Part 1 – Technical Evaluation, Mandatory Technical Criteria, M2 with the following:

| MANDATORY TECHNICAL CRITERIA | | |
|------------------------------|---|--|
| NUMBER | DESCRIPTION | BID REFERENCE (page, section, etc.) |
| M2 | <p><u>ANNUAL INFLUENZA VACCINE CAPACITY</u> <u>Item 1a and 1b – Quadrivalent Influenza Vaccine (QIV)</u> <u>for age indication of 6 months and above – Pre-filled Syringe (PFS) and Multi-dose Vial (MDV):</u></p> <p>The Bidder must demonstrate that it will have the capacity to produce and deliver up to 1.725M doses of QIV in PFS and/or 4.4M doses of QIV in MDV for age indication 6 months and above, as described in Annex A - Requirement, for the contract term and each of the options years.</p> <p><u>Item 2a and 2b – Quadrivalent Influenza Vaccine (QIV)</u> <u>for age indication of 5 years of age and above – Pre-filled Syringe (PFS) and Multi-dose Vial (MDV):</u></p> <p>The Bidder must demonstrate that it will have the capacity to produce and deliver up 340K doses of QIV PFS and/or 1M doses of QIV in MDV for age indication 5 years of age and above, as described in Annex A - Requirement, for the contract term and each of the options years.</p> | |

REPACE the closing date with January 26, 2022.

ALL OTHER TERMS AND CONDITIONS REMAIN UNCHANGED.